BioMarin Pharmaceutical Inc.
Prices may be delayed up to 20 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| BMRN.MX | CONCORDBIO.NS | BIOCON.NS | BBIO | 0NZU.IL | ROIV | |
|---|---|---|---|---|---|---|
| Market cap | 197.76B | 140.75B | 592.87B | 15.17B | 14.40B | 27.61B |
| P/E (TTM) | — | 50.4 | 121.5 | — | — | — |
| Forward P/E | — | 32.5 | 33.3 | -225.0 | — | -27.5 |
| Price/book | 1.7 | 6.9 | 1.7 | -5.9 | 8.1 | 6.5 |
| Dividend yield | — | 0.58% | 0.15% | — | — | — |
| 1-year change | +3.24% | −7.11% | −10.58% | +24.17% | −43.38% | +85.85% |
| Today | 0.00% | +2.62% | +5.10% | +5.21% | +1.34% | +6.08% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All BMRN.MX news ›MRM Health and Biocodex establish strategic partnership to strengthen future commercial supply capabilities for CORAL®-based medicines
Planned €15 million investment by Biocodex in specialized anaerobic manufacturing infrastructure will establish an additional pathway for MH002 and other MRM Health programs, from clinical development toward potential commercial supply 5…
BioMarin Pharmaceutical Inc. 2026 Q3 - Results - Earnings Call Presentation
2026-11-05. The following slide deck was published by BioMarin Pharmaceutical Inc. The following slide deck was published by BioMarin Pharmaceutical Inc. in conjunction with their 2026 Q3 earnings call. Q3: 2026-11-02 Earnings Summary
BioMar reports best ever Q3 results
News - BioMar reports best ever Q3 results Fish Farmer BioMar reports best ever Q3 results Please Login/register for FREE to continue reading Fish Farmer Your FREE registration gives you access to all our content: news and feature…
BioMar looks to M&A as it pushes for lasting shift to alternative feed
IntraFish BioMar looks to M&A as it pushes for lasting shift to alternative feed Acquisitions remain part of the feed giant's growth strategy, and the most likely target is a shrimp feed business in South America or Asia, the CE
BioMarin: Better Risk-Reward Ahead Of Three FDA Decisions
BioMarin is a speculative Buy as lower valuation, FDA catalysts, and Voxzogo growth potential may reward long-term investors. Click to read more on BMRN stock. - BioMarin’s lower valuation and broader commercial portfolio now offer a…
Biocon Q2 Profit Falls 52% YoY 41 Crore; Co. Secures USD 400 Million Brazil Biosimilar Deal
Biocon’s consolidated operating revenue rose 2 per cent year-on-year to Rs 4,389 crore during the quarter. The company’s biopharma revenue grew 5 per cent to Rs 3,583 crore. Within the segment, biosimilars revenue increased 3 per cent…
Cellectar Biosciences (CLRB) Set to Release Quarterly Earnings on Tuesday
Posted by Sarita Garza on Nov 4th, 2026 Cellectar Biosciences (NASDAQ:CLRB – Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.57) EPS for the quarter,…
BioMarin to Participate in Upcoming Investor Conferences
PR Newswire - Stifel Healthcare Conference, November 11 at 3:20 pm EST - UBS Global Biopharma Conference, November 16 at 9:20 am GMT - Jefferies Global Healthcare Conference, November 17 at 11:30 am GMT SAN RAFAEL, Calif., Nov. 4, 2026 /PRN
BioMarin Pharmaceutical Inc. Stock 12‑Month Price Target Cut to $90.85, Implies 58% Upside
TradingView BioMarin Pharmaceutical Inc. Stock 12‑Month Price Target Cut to $90.85, Implies 58% Upside - According to estimates from 26 analysts, BioMarin Pharmaceutical Inc. stock's average price target has
BioMarin anticipates $3.8B-$3.9B 2026 revenue while flagging $70M order deferrals
BioMarin Q3 2026 earnings: revenue topped $1B, guidance was updated on order delays, and pipeline momentum continued. Earnings Call Insights: BioMarin Pharmaceutical Inc. (BMRN) Q3 2026 "Strong demand across our diversified portfolio of…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- themarketsdaily.com11
- seekingalpha.com8
- prnewswire.com5
- marketscreener.com4
- theglobeandmail.com3
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 51 articles, not a forecast.